Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine

J Virol. 1994 May;68(5):3145-53. doi: 10.1128/JVI.68.5.3145-3153.1994.

Abstract

Efforts to induce broadly reactive immunity against human immunodeficiency virus type 1 (HIV-1) have been impaired by the extent of sequence variation exhibited by this lentivirus. Cytotoxic T lymphocytes (CTL) specific for other viruses such as influenza virus have been shown to mediate immunity against divergent viral strains, a property that is related to the ability of CTL to recognize processed antigen derived from conserved viral proteins. A recent candidate HIV-1 vaccine regimen has been described in which subjects receive a primary immunization with a recombinant vaccinia virus expressing gp160 and then a booster immunization with recombinant gp160. Volunteers immunized with this regimen have exhibited augmented humoral responses and have also developed CD4+ and CD8+ CTL specific for gp160. In this report, we have identified the epitopes recognized by CD4+ and CD8+ CTL obtained from two vaccines. An immunodominant CD8+ CTL response was HLA-A3.1 restricted and recognized a 10-amino-acid epitope (gp120/38-47) in a highly conserved region of gp120. CTL specific for the epitope gp120/38-47 were able to lyse targets sensitized with peptides corresponding to all known natural sequence variants in this region. In addition, other HLA class I-restricted CTL epitopes were identified in relatively conserved regions of gp120 and gp41, and CD4+ CTL were shown to recognize two different regions of gp120. Thus, in these two volunteers, immunization with a single strain of HIV-1 induced CD4+ and CD8+ CTL that are specific for multiple conserved regions of HIV-1 and would be expected to recognize a broad range of viral isolates.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • CD4-Positive T-Lymphocytes / immunology
  • CD8 Antigens / immunology
  • Clinical Trials as Topic
  • Clone Cells / immunology
  • Conserved Sequence / immunology
  • Gene Products, env / immunology*
  • HIV Envelope Protein gp120 / immunology
  • HIV Envelope Protein gp160
  • HIV Envelope Protein gp41 / immunology
  • HIV Seronegativity
  • HIV-1 / immunology*
  • HLA-A Antigens / immunology
  • HLA-A3 Antigen
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Immunization*
  • Immunodominant Epitopes / immunology
  • Molecular Sequence Data
  • Protein Precursors / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • AIDS Vaccines
  • CD8 Antigens
  • Gene Products, env
  • HIV Envelope Protein gp120
  • HIV Envelope Protein gp160
  • HIV Envelope Protein gp41
  • HLA-A Antigens
  • HLA-A*03:01:01:01 antigen
  • HLA-A3 Antigen
  • Histocompatibility Antigens Class I
  • Immunodominant Epitopes
  • Protein Precursors